CASP1 and Parkinson disease: Several NLRP3 inflammasome inhibitors have been identified that can effectively suppress neuroinflammation in PD by directly blocking NLRP3 activation, preventing its oligomerization, or inhibiting downstream cytokine production such as IL-1β, IL-18, and active Caspase-1.